Detalhe da pesquisa
1.
Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function.
J Neurooncol
; 145(3): 429-439, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31686330
2.
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
J Transl Med
; 14: 46, 2016 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26861698
3.
Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors.
Am J Cancer Res
; 10(11): 3765-3783, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33294266
4.
Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Neuro Oncol
; 22(9): 1302-1314, 2020 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32166329
5.
Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma.
Cancer Cell
; 35(6): 868-884.e6, 2019 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31185211
6.
REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Neuro Oncol
; 21(6): 775-785, 2019 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30953587
7.
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
Clin Cancer Res
; 25(22): 6801-6814, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31455679
8.
The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.
Oncotarget
; 9(12): 10497-10509, 2018 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29535822
9.
An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Nat Med
; 24(7): 1036-1046, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29892070
10.
Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma.
Oncotarget
; 8(57): 96970-96983, 2017 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29228586
11.
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Neuro Oncol
; 18(9): 1230-41, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26965451
12.
Mechanisms of action of rapamycin in gliomas.
Neuro Oncol
; 7(1): 1-11, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15701277
13.
Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.
Oncotarget
; 6(31): 31479-92, 2015 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26362401
14.
Neutrophils promote the malignant glioma phenotype through S100A4.
Clin Cancer Res
; 20(1): 187-98, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24240114
15.
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Clin Cancer Res
; 19(16): 4392-403, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23804423
16.
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Neuro Oncol
; 14(11): 1379-92, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22965162
17.
Glioma-associated cancer-initiating cells induce immunosuppression.
Clin Cancer Res
; 16(2): 461-73, 2010 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20068105
18.
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.
Mol Cancer Ther
; 9(1): 67-78, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20053772